Impact of Geographic Region on the COMMANDER-HF Trial

Tromp, 2019, Heart failure around the world, Eur J Heart Fail, 21, 1187, 10.1002/ejhf.1585 Ferreira, 2015, Geographic differences in heart failure trials, Eur J Heart Fail, 17, 893, 10.1002/ejhf.326 Pfeffer, 2015, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, Circulation, 131, 34, 10.1161/CIRCULATIONAHA.114.013255 Dewan, 2019, Income inequality and outcomes in heart failure: a global between-country analysis, J Am Coll Cardiol HF, 7, 336 Ferreira, 2019, Income level and inequality as complement to geographical differences in cardiovascular trials, Am Heart J, 218, 66, 10.1016/j.ahj.2019.08.019 McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303 Packer, 2019, Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial, Eur J Heart Fail, 21, 1270, 10.1002/ejhf.1536 Armstrong, 2020, Vericiguat in patients with heart failure and reduced ejection fraction, N Engl J Med, 382, 1883, 10.1056/NEJMoa1915928 Zannad, 2015, Eur J Heart Fail, 17, 735, 10.1002/ejhf.266 Zannad, 2018, Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease, N Engl J Med, 379, 1332, 10.1056/NEJMoa1808848 Mehra, 2019, A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial, Eur Heart J, 40, 3593, 10.1093/eurheartj/ehz427 Greenberg, 2019, Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial, JAMA Cardiol, 4, 515, 10.1001/jamacardio.2019.1049 Cunningham, 2020, Natriuretic peptide-based inclusion criteria in a heart failure clinical trial: insights from COMMANDER HF, J Am Coll Cardiol HF Baglin, 2012, Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology, Br J Haematol, 159, 427, 10.1111/bjh.12052 Kubitza, 2005, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor, Clin Pharmacol Ther, 78, 412, 10.1016/j.clpt.2005.06.011 Gosselin, 2018, International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants, Thromb Haemost, 118, 437, 10.1055/s-0038-1627480 McMurray, 2014, Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, 371, 993, 10.1056/NEJMoa1409077 Kristensen, 2016, Geographic variations in the PARADIGM-HF heart failure trial, Eur Heart J, 37, 3167, 10.1093/eurheartj/ehw226 Vaduganathan, 2018, Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years, Eur J Heart Fail, 20, 1068, 10.1002/ejhf.1130 de Denus, 2017, Spironolactone metabolites in TOPCAT--- new insights into regional variation, N Engl J Med, 376, 1690, 10.1056/NEJMc1612601 Gagnon, 2017, Patient beliefs have a greater impact than barriers on medication adherence in a community health center, J Am Board Fam Med, 30, 331, 10.3122/jabfm.2017.03.160129 Sjölander, 2013, The association between patients' beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey, BMJ Open, 3, 10.1136/bmjopen-2013-003551 Vogler, 2015, Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries, Int J Equity Health, 14, 124, 10.1186/s12939-015-0261-0 Blaschke, 2012, Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories, Annu Rev Pharmacol Toxicol, 52, 275, 10.1146/annurev-pharmtox-011711-113247 Pocock, 2002, Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems, Stat Med, 21, 2917, 10.1002/sim.1296